Gazyva 1 000 mg Concentrate solution for infusion
PDF Leaflet Revision Date: 29 July 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of chronic lymphocytic leukaemia and follicular lymphoma.
Dosage (summary)
1,000 mg IV on Day 1, 8, 15 of Cycle 1; then 1,000 mg IV on Day 1 of subsequent cycles.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Avoid in pregnancy; use contraception during and for 18 months after treatment. Discontinue breastfeeding during therapy.
Key Drug Interactions
- Bendamustine
- CHOP
- Chlorambucil
Contraindications
- Hypersensitivity to obinutuzumab
- Active infections
- Active hepatitis B
- Live vaccines
- Pregnancy
Common side effects
- Infusion related reactions
- Neutropenia
- Thrombocytopenia
- Infections
- Fatigue
Counselling Points
- Monitor for infusion reactions
- Hydration and prophylaxis for TLS
- Avoid live vaccines
- Report any signs of infection
Serious warnings
- Severe infusion related reactions
- Tumour lysis syndrome
- Hepatitis B reactivation
- Progressive multifocal leukoencephalopathy
Important Disclaimer
The Gazyva 1 000 mg Concentrate solution for infusion professional information leaflet below is the property of Roche Products and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
